Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection
David J. DiLillo, … , Patrick C. Wilson, Jeffrey V. Ravetch
David J. DiLillo, … , Patrick C. Wilson, Jeffrey V. Ravetch
Published January 5, 2016
Citation Information: J Clin Invest. 2016;126(2):605-610. https://doi.org/10.1172/JCI84428.
View: Text | PDF
Concise Communication Immunology

Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection

  • Text
  • PDF
Abstract

In vivo protection by antimicrobial neutralizing Abs can require the contribution of effector functions mediated by Fc-Fcγ receptor (Fc-FcγR) interactions for optimal efficacy. In influenza, broadly neutralizing anti-hemagglutinin (anti-HA) stalk mAbs require Fc-FcγR interactions to mediate in vivo protection, but strain-specific anti-HA head mAbs do not. Whether this rule applies only to anti-stalk Abs or is applicable to any broadly neutralizing Ab (bNAb) against influenza is unknown. Here, we characterized the contribution of Fc-FcγR interactions during in vivo protection for a panel of 13 anti-HA mAbs, including bNAbs and non-neutralizing Abs, against both the stalk and head domains. All classes of broadly binding anti-HA mAbs required Fc-FcγR interactions to provide protection in vivo, including those mAbs that bind the HA head and those that do not neutralize virus in vitro. Further, a broadly neutralizing anti-neuraminidase (anti-NA) mAb also required FcγRs to provide protection in vivo, but a strain-specific anti-NA mAb did not. Thus, these findings suggest that the breadth of reactivity of anti-influenza Abs, regardless of their epitope, necessitates interactions with FcγRs on effector cell populations to mediate in vivo protection. These findings will guide the design of antiviral Ab therapeutics and inform vaccine design to elicit Abs with optimal binding properties and effector functions.

Authors

David J. DiLillo, Peter Palese, Patrick C. Wilson, Jeffrey V. Ravetch

×

Figure 3

Broadly neutralizing anti-NA mAb requires Fc-FcγR interactions to mediate protection in vivo, but strain-specific anti-NA mAb does not.

Options: View larger image (or click on image) Download as PowerPoint
Broadly neutralizing anti-NA mAb requires Fc-FcγR interactions to mediat...
(A) Broadly neutralizing anti-HA stalk mAb FI6 (red circles), strain-specific anti-HA head mAb 4C04 (blue squares), strain-specific anti-NA mAb 3C02 (green circles), and broadly neutralizing anti-NA mAb 3C05 (green squares) neutralization of Neth09 virus. Values represent the mean ±SEM of duplicate samples. (B and C) Mice were given the indicated doses of IgG2a (red circles) or DA265-mutant (blue squares) 3C02 (B) or 3C05 (C) mAb or PBS (black triangles) before Neth09 viral infection. Values represent the mean ± SEM percentage of weight change compared with day-0 values (left panels) and percentage of survival (right panels). n = 4–5 mice per group. Significant differences between the IgG2a sample and DA265 sample are shown. **P < 0.01 by Student’s t test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts